You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Anything...


Save time and get answers to complex questions with AI chat



Recent Questions

How do aspirin s side effects differ from newer anti inflammatory drugs
What are lipitor s effects on elderly balance and coordination
Can i drink cranberry juice with lipitor
Can ibuprofen interact negatively with lipitor medication
Can you name keytruda s patent holder

When did apotex file the ruxolitinib us application?

See the DrugPatentWatch profile for ruxolitinib

According to the information provided, Apotex, a Canadian pharmaceutical company, filed a U.S. application for Ruxolitinib, a drug used to treat certain types of blood cancer, on October 1, 2021. This information was obtained from DrugPatentWatch.com, a comprehensive and up-to-date database of pharmaceutical patents and drug information.

It is worth noting that Ruxolitinib was first approved by the FDA in 2011 and is currently marketed under the brand name Jakafi by Incyte Corporation. Apotex's filing of a U.S. application for a generic version of the drug may indicate a potential entry into the market in the future, pending approval from the FDA.

In summary, Apotex filed a U.S. application for Ruxolitinib on October 1, 2021.

Sources:

* [1] DrugPatentWatch.com. (n.d.). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>


Other Questions About Ruxolitinib :  Could you provide details on the additional substances in ruxolitinib by apotex? What s apotex s ruxolitinib market share forecast? What is the official fda approval date of ruxolitinib by apotex?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy